Relationship between 18F-FDG PET SUV with Partial Volume Correction and Histology in Gastric and Gastro-Oesophageal Cancer
Author(s)
Francesca Gallivanone*,
Carla Canevari,
Paola Mapelli,
Maria Picchio,
Luigi Gianolli,
Maria Carla Gilardi,
Isabella Castiglioni
Affiliation(s)
Institute of Molecular Bioimaging and Physiology (IBFM)-CNR, Milan, Italy. Nuclear Medicine Department, Hospital San Raffaele, Milan, Italy. University of Milano-Bicocca, Milan, Italy. Tecnomed Foundation, University of Milano-Bicocca, Milan, Italy.
Institute of Molecular Bioimaging and Physiology (IBFM)-CNR, Milan, Italy. Nuclear Medicine Department, Hospital San Raffaele, Milan, Italy. University of Milano-Bicocca, Milan, Italy. Tecnomed Foundation, University of Milano-Bicocca, Milan, Italy.
ABSTRACT
In vivo molecular imaging techniques is increasingly used in the management of oncological patients, allowing different aspects of oncological pathologies to be assessed (e.g. metabolism, hypoxia) non invasively. The possibility to extract indexes of disease from in vivo biomedical images and to associate them with their biological drivers opens new pro-spective on the role of in vivo molecular imaging and expedites the translation of novel biomarkers from the bench to the clinical environment. In this work we investigate the relationship between 18F-FDG uptake measured by Body- Weight Standardized Uptake Value (SUVBW) as index of cell glucose metabolism, and histological indices for gastric and gastro-oesophageal cancer. For this purpose, Partial Volume Effect Correction (PVC) has been properly compen- sated prior to the measurement of the PET index (PVC-SUVsub>BW). The correlation of 18F-FDG PVC-SUVBW with histol- ogy data was evaluated by bivariate and multivariate statistical analysis. Although obtained in a limited number of pa- tients, our results suggest that correlations can be found when PVC is applied to SUVBW and that 18F-FDG PET can provide information on biological characteristics of gastric and gastro-oesophageal cancer lesions.
In vivo molecular imaging techniques is increasingly used in the management of oncological patients, allowing different aspects of oncological pathologies to be assessed (e.g. metabolism, hypoxia) non invasively. The possibility to extract indexes of disease from in vivo biomedical images and to associate them with their biological drivers opens new pro-spective on the role of in vivo molecular imaging and expedites the translation of novel biomarkers from the bench to the clinical environment. In this work we investigate the relationship between 18F-FDG uptake measured by Body- Weight Standardized Uptake Value (SUVBW) as index of cell glucose metabolism, and histological indices for gastric and gastro-oesophageal cancer. For this purpose, Partial Volume Effect Correction (PVC) has been properly compen- sated prior to the measurement of the PET index (PVC-SUVsub>BW). The correlation of 18F-FDG PVC-SUVBW with histol- ogy data was evaluated by bivariate and multivariate statistical analysis. Although obtained in a limited number of pa- tients, our results suggest that correlations can be found when PVC is applied to SUVBW and that 18F-FDG PET can provide information on biological characteristics of gastric and gastro-oesophageal cancer lesions.
Cite this paper
F. Gallivanone, C. Canevari, P. Mapelli, M. Picchio, L. Gianolli, M. Gilardi and I. Castiglioni, "Relationship between 18F-FDG PET SUV with Partial Volume Correction and Histology in Gastric and Gastro-Oesophageal Cancer," Open Journal of Medical Imaging, Vol. 2 No. 3, 2012, pp. 96-99. doi: 10.4236/ojmi.2012.23017.
F. Gallivanone, C. Canevari, P. Mapelli, M. Picchio, L. Gianolli, M. Gilardi and I. Castiglioni, "Relationship between 18F-FDG PET SUV with Partial Volume Correction and Histology in Gastric and Gastro-Oesophageal Cancer," Open Journal of Medical Imaging, Vol. 2 No. 3, 2012, pp. 96-99. doi: 10.4236/ojmi.2012.23017.
References
[1] M. Soret, S. L. Bacharach and I. Buvat, “Partial-Volume Effect in PET Tumor Imaging,” Journal of Nuclear Medicine, Vol. 48, No. 6, 2007, pp. 932-945. doi:10.2967/jnumed.106.035774 [2] F. Gallivanone, A. Stefano, C. Canevari, L. Gianolli, C. Messa, M. C. Gilardi and I. Castiglioni, “PVE Correction in PET-CT Whole-Body Oncological Studies from PVEAffected Images,” IEEE Transactions on Nuclear Science, Vol. 58, No. 3, 2011, pp. 736-747. doi:10.1109/TNS.2011.2108316 [3] I. Castiglioni, F. Gallivanone and A. Stefano, “TOUCH SUV, SIAE registration number 007449-D006667,” 2009. [4] A. Stefano, F. Gallivanone, E. Grosso, G. Russo, C. Messa, V. Tripoli, M. C. Gilardi and I. Castiglioni “TOUCHSUV: A Touchscreen-Assisted Tool for Quantitative, Reproducible, Clinically Feasible and Collaborative Diagnostic Reporting of Whole-Body PET-CT Studies,” Software Engineering, Vol. 1, No. 1, 2011, pp. 1-8. [5] W. L. Wong and R. J. Chambers, “Role of PET/PET CT in the Staging and Restaging of Thoracic Oesophageal Cancer and Gastro-Oesophageal Cancer: A Literature Review,” Abdominal Imaging, Vol. 33, No. 2, 2008, pp. 183-190. doi:10.1007/s00261-007-9241-1 [6] G. Lucignani, “Oesophageal Cancer: Can Imaging Improve Its Assessment?” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 10, 2008, pp. 1921-1927. doi:10.1007/s00259-008-0884-0 [7] T. K. Ha, Y. Y. Choi, S. Y. Song and S. J. Kwon, “F18Fluorodeoxyglucose-Positron Emission Tomography and Computed Tomography Is Not Accurate in Preoperative Staging of Gastric Cancer,” Journal of the Korean Surgical Society, Vol. 81, No. 2, 2011, pp. 104-110. doi:10.4174/jkss.2011.81.2.104 [8] H. Miyata, Y. Doki, T. Yasuda, M. Yamasaki, I. Higuchi and Y. Makari, “Evaluation of Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography in Superficial Squamous Cell Carcinomas of the Thoracic Esophagus,” Diseases of the Esophagus, Vol. 21, No. 2, 2008, pp. 144-150. doi:10.1111/j.1442-2050.2007.00743.x [9] M. Westerterp, G. W. Sloof, O. S. Hoekstra, F. J. T. Kate, G. A. Meijer and J. B. Reitsma, “18FDG Uptake in Oesophageal Adenocarcinoma: Linking Biology and Outcome,” Journal of Cancer Research and Clinical Oncology, Vol. 134, No. 2, 2008, pp. 227-236. doi:10.1007/s00432-007-0275-0
[1] M. Soret, S. L. Bacharach and I. Buvat, “Partial-Volume Effect in PET Tumor Imaging,” Journal of Nuclear Medicine, Vol. 48, No. 6, 2007, pp. 932-945. doi:10.2967/jnumed.106.035774 [2] F. Gallivanone, A. Stefano, C. Canevari, L. Gianolli, C. Messa, M. C. Gilardi and I. Castiglioni, “PVE Correction in PET-CT Whole-Body Oncological Studies from PVEAffected Images,” IEEE Transactions on Nuclear Science, Vol. 58, No. 3, 2011, pp. 736-747. doi:10.1109/TNS.2011.2108316 [3] I. Castiglioni, F. Gallivanone and A. Stefano, “TOUCH SUV, SIAE registration number 007449-D006667,” 2009. [4] A. Stefano, F. Gallivanone, E. Grosso, G. Russo, C. Messa, V. Tripoli, M. C. Gilardi and I. Castiglioni “TOUCHSUV: A Touchscreen-Assisted Tool for Quantitative, Reproducible, Clinically Feasible and Collaborative Diagnostic Reporting of Whole-Body PET-CT Studies,” Software Engineering, Vol. 1, No. 1, 2011, pp. 1-8. [5] W. L. Wong and R. J. Chambers, “Role of PET/PET CT in the Staging and Restaging of Thoracic Oesophageal Cancer and Gastro-Oesophageal Cancer: A Literature Review,” Abdominal Imaging, Vol. 33, No. 2, 2008, pp. 183-190. doi:10.1007/s00261-007-9241-1 [6] G. Lucignani, “Oesophageal Cancer: Can Imaging Improve Its Assessment?” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 10, 2008, pp. 1921-1927. doi:10.1007/s00259-008-0884-0 [7] T. K. Ha, Y. Y. Choi, S. Y. Song and S. J. Kwon, “F18Fluorodeoxyglucose-Positron Emission Tomography and Computed Tomography Is Not Accurate in Preoperative Staging of Gastric Cancer,” Journal of the Korean Surgical Society, Vol. 81, No. 2, 2011, pp. 104-110. doi:10.4174/jkss.2011.81.2.104 [8] H. Miyata, Y. Doki, T. Yasuda, M. Yamasaki, I. Higuchi and Y. Makari, “Evaluation of Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography in Superficial Squamous Cell Carcinomas of the Thoracic Esophagus,” Diseases of the Esophagus, Vol. 21, No. 2, 2008, pp. 144-150. doi:10.1111/j.1442-2050.2007.00743.x [9] M. Westerterp, G. W. Sloof, O. S. Hoekstra, F. J. T. Kate, G. A. Meijer and J. B. Reitsma, “18FDG Uptake in Oesophageal Adenocarcinoma: Linking Biology and Outcome,” Journal of Cancer Research and Clinical Oncology, Vol. 134, No. 2, 2008, pp. 227-236. doi:10.1007/s00432-007-0275-0